Mitochondrial Myopathies
27
8
8
19
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 27 trials
100.0%
+13.5% vs benchmark
4%
1 trials in Phase 3/4
5%
1 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (27)
Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders
Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders
Validation of Oxygen Nanosensor in Mitochondrial Myopathy
Validation of Nanosensor Oxygen Measurement
Applying pGz in Mitochondrial Disease
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance
Human Mitochondrial Stress-driven Obesity Resistance
Mitochondrial Dysfunctions Driving Insulin Resistance
Global Registry and Natural History Study for Mitochondrial Disorders
RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR
Home Based Personalized Training and Video Consultation in Mitochondrial Myopathies: Study of Efficacy and Tolerance.
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine
Effect and Safety MABs Administration m.3243A>G Mutation Carriers
mtDNA Mutation Load Analysis in Mesoangioblasts
MABs Therapy m.3243A>G Mutation Carriers
Nicotinamide Riboside and Mitochondrial Biogenesis
Niacin Supplementation in Healthy Controls and Mitochondrial Myopathy Patients